Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.
Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, Sharon TD, Pick M, Lebel E, Shaulov A, Cohen YC, Avivi I, Cohen CJ, Stepensky P, Gatt ME. Kfir-Erenfeld S, et al. Among authors: shaulov a. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. Clin Cancer Res. 2022. PMID: 36107221 Clinical Trial.
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Goldschmidt N, Horowitz NA, Heffes V, Darawshy F, Mashiach T, Shaulov A, Gatt ME, Dann EJ. Goldschmidt N, et al. Among authors: shaulov a. Leuk Lymphoma. 2019 Aug;60(8):1890-1898. doi: 10.1080/10428194.2018.1564823. Epub 2019 Jan 28. Leuk Lymphoma. 2019. PMID: 30689468
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni C, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA. Katodritou E, et al. Among authors: shaulov a. Am J Hematol. 2020 May;95(5):465-471. doi: 10.1002/ajh.25755. Epub 2020 Mar 2. Am J Hematol. 2020. PMID: 32048329 Free article.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, Kreiniz N, Tadmor T, Trestman S, Vitkon R, Rouvio O, Shvetz O, Shaulov A, Ziv-Baran T, Avivi I. Cohen YC, et al. Among authors: shaulov a. Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32193630
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study.
Shragai T, Gatt ME, Shaulov A, Katodritou E, Triantafyllou T, Lavi N, Pouli A, Sioni A, Vaxman I, Zektser M, Ganzel C, Benyamini N, Trestman S, Ziv-Baran T, Adam Y, Cohen YC, Avivi I. Shragai T, et al. Among authors: shaulov a. Leuk Res. 2021 Feb;101:106498. doi: 10.1016/j.leukres.2020.106498. Epub 2020 Dec 31. Leuk Res. 2021. PMID: 33453475 Clinical Trial.
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Lebel E, Goldschmidt N, Siegal T, Lossos A, Rosenberg S, Makranz C, Linetski E, Gatt ME, Gural A, Saban R, Lavie D, Vainstein V, Zimran E, Avni B, Grisaro S, Shaulov A, Nachmias B. Lebel E, et al. Among authors: shaulov a. Leuk Lymphoma. 2022 Sep;63(9):2102-2108. doi: 10.1080/10428194.2022.2064996. Epub 2022 May 2. Leuk Lymphoma. 2022. PMID: 35491706
83 results